key: cord-0327310-w2d644zr
authors: Vihta, K.-D.; Pouwels, K. B.; Peto, T.; Pritchard, E.; Eyre, D. W.; House, T.; Gethings, O.; Studley, R.; Rourke, E.; Cook, D.; Diamond, I.; Crook, D.; Matthews, P. C.; Stoesser, N.; Walker, A. S.; team, COVID-19 Infection Survey
title: Symptoms and SARS-CoV-2 positivity in the general population in the UK
date: 2021-08-24
journal: nan
DOI: 10.1101/2021.08.19.21262231
sha: bbaeb31d222190964fc8fec39ba6220aa0c2fa96
doc_id: 327310
cord_uid: w2d644zr

Background: Several community-based studies have assessed the ability of different symptoms to identify COVID-19 infections, but few have compared symptoms over time (reflecting SARS-CoV-2 variants) and by vaccination status. Methods: Using data and samples collected by the COVID-19 Infection Survey at regular visits to representative households across the UK, we compared symptoms in new PCR-positives and comparator test-negative controls. Results: From 26/4/2020-7/8/2021, 27,869 SARS-CoV-2 PCR-positive episodes occurred in 27,692 participants (median 42 years (IQR 22-58)); 13,427 (48%) self-reported symptoms ("symptomatic positive episodes"). The comparator group comprised 3,806,692 test-negative visits (457,215 participants); 130,612 (3%) self-reported symptoms ("symptomatic negative visits"). Reporting of any symptoms in positive episodes varied over calendar time, reflecting changes in prevalence of variants, incidental changes (e.g. seasonal pathogens, schools re-opening) and vaccination roll-out. There was a small increase in sore throat reporting in symptomatic positive episodes and negative visits from April-2021. After May-2021 when Delta emerged there were substantial increases in headache and fever in positives, but not in negatives. Although specific symptom reporting in symptomatic positive episodes vs. negative visits varied by age, sex, and ethnicity, only small improvements in symptom-based infection detection were obtained; e.g. adding fatigue/weakness or all eight symptoms to the classic four symptoms (cough, fever, loss of taste/smell) increased sensitivity from 74% to 81% to 90% but tests per positive from 4.6 to 5.3 to 8.7. Conclusions: Whilst SARS-CoV-2-associated symptoms vary by variant, vaccination status and demographics, differences are modest and do not warrant large-scale changes to targeted testing approaches given resource implications.

Fatigue/weakness, cough, and headache were the most frequently reported symptoms in positive 161 episodes (54%, 54%, 52% of symptomatic positive episodes; Fig.1 ). However, headache and cough 162 were most frequently reported amongst negative visits too, together with sore throat (23%, 22%, 163 22%; Fig.1 ). Loss of taste/smell were the most specific symptoms for SARS-CoV-2 positivity (33%/33% 164 positive episodes, only 2%/2% negative visits). In positive episodes, loss of taste or smell were 165 commonly co-reported, as were gastrointestinal symptoms, and headache/myalgia/fatigue. 166 Symptom co-reporting in symptomatic positive episodes was generally similar regardless of Ct, 167 variant, vaccination status or age (Fig.S2) , although myalgia was less strongly co-reported with 168 headache/fatigue in those 6-15y, with Delta and in those 14d post-second vaccination. Patterns 169 were broadly similar in negatives, except cough and sore throat were more commonly co-reported. 170 171 Symptomatology varied significantly by variant (Fig.1) ; with a smaller percentage of symptomatic 172 positive episodes reporting loss of taste/smell for Alpha-compatible (31%/28%) than wild-type 173 (38%/36%) or Delta-compatible (38%/39%) symptomatic positive episodes (p<0.0001). 174

Fever/headache/sore throat had the largest difference between symptoms reported for Alpha-175 compatible (37%/56%/38%) and Delta-compatible (46%/62%/50%) symptomatic positive episodes 176 (p<0.0001). Cough and fatigue/weakness had the largest differences between wild-type (50%/50%) 177 vs Alpha-compatible (61%/61%) or Delta-compatible (64%/60%) symptomatic positive episodes 178 (p<0.0001). In general, specific symptoms were reported slightly more in symptomatic positive 179 episodes 14d from second vaccination versus those unvaccinated or 21d from first vaccination. 180 181 Symptomatology over calendar time 182

Adjusting for age, sex and ethnicity, the probability of symptoms being reported amongst positive 183 episodes was reasonably stable after August-2020 given changes in incidence and sample size (Fig.2,  184 top panels), with fluctuations likely reflecting school return in September-2020 and March-2021, plus 185 . CC-BY 4.0 International license It is made available under a perpetuity.

is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted August 24, 2021. ; https://doi.org/10.1101 https://doi.org/10. /2021 the emergence of Alpha and Delta in November-2020 and May-2021. Smaller fluctuations in 186 reporting any symptoms in negative visits (Fig.2 , bottom panels) mirrored those in positive episodes. 187

The percentage of symptomatic positive episodes reporting each specific symptom generally 188 increased over time, consistent with increasing awareness. Reporting of most specific symptoms 189 except loss of taste/smell temporarily peaked in January-2021, consistent with the peak in Alpha, 190 then remained approximately constant through to May-2021, before increasing again, markedly so 191 for headache, cough and fever after Delta became dominant. Increases in cough and sore throat in 192 symptomatic negative visits occurred after school return in September-2020 , in January-2021 schools were shut, and from early April-2021, consistent with other respiratory viruses. The winter 194 months saw particular increases in gastrointestinal symptoms, fatigue/weakness, myalgia and 195 headache in symptomatic negative visits, consistent with the presence of other common seasonal 196 pathogens. 197 198 Symptomatology by age, sex and ethnicity 199

All symptoms showed marked variation across age in both positive episodes and negative visits, 200 mostly being reported less in children and elderly adults (Fig.3) . Loss of taste/smell were most 201 frequently reported in symptomatic positive episodes in those aged ~20y, decreasing gradually at 202 older ages; both were rarely reported amongst symptomatic negative visits, consistent with their 203 high specificity for SARS-CoV-2, although slightly more in the elderly. Sore throat and headache also 204 peaked in symptomatic positive episodes and negative visits in late adolescence, but were common 205 regardless of positivity. High proportions reported cough, relatively similarly amongst symptomatic 206 positive episodes and negative visits to ~10y, therefore without discriminating; however, above 20y 207 the proportion reporting cough was more than double in symptomatic positive episodes, and 208 increased to ~60y, as did fatigue/weakness, shortness of breath, and diarrhoea. 209 210 . CC-BY 4.0 International license It is made available under a perpetuity.

is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted August 24, 2021. ; https://doi.org/10.1101 https://doi.org/10. /2021 Adjusting for calendar time, age and ethnicity, women were generally more likely than men to report 211 most symptoms (Fig.4) . Increased reporting in women was significantly greater in symptomatic 212 positive episodes than negative visits for loss of smell and taste, diarrhoea and shortness of breath, 213 and significantly smaller for headache and sore throat (all heterogeneity p<0.01). Whilst there was 214 no evidence of differential reporting of fever between male and female symptomatic negative visits, 215 female symptomatic positive episodes were significantly less likely to report fever (p<0.001). 216 217 After adjusting for calendar time, age and sex, in both symptomatic positive episodes and negative 218 visits, non-white ethnic groups were more likely to report fever than white ethnic groups, and less 219 likely to report headache, nausea/vomiting and shortness of breath (Fig.4) . Those from non-white 220 ethnic groups were less likely to report loss of taste or smell and shortness of breath to a significantly 221 greater degree in symptomatic positive episodes versus negative visits (all p<0.01). is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted August 24, 2021. ; https://doi.org/10.1101 https://doi.org/10. /2021 showed little variation. Interestingly, prevalence of reported loss of taste/smell increased 235 substantially from ~30% to ~45% between Ct 15-27.5, with smaller increases for shortness of breath. 236 237 Symptom combinations predicting symptomatic PCR-positive episodes 238

Over the whole study, PPV of any evidence of symptoms for identifying PCR-positive episodes was 239 9%. Including any of the 12 elicited symptoms by definition maximised sensitivity (90% of 240 symptomatic positive episodes reported at least one specific symptom; remainder reported any 241 other symptom considered COVID-19 related only), but substantially increased TPC (8.7) and number 242 of tests (2.3-fold) compared with using the four classic (cough, fever, loss of taste/smell) symptoms 243 (74%, 4.6, 1-fold). For a fixed number of 1-8 symptoms, the choice of whether to maximise sensitivity 244 or area under the receiver operating characteristic (AUROC) curve, or to minimise TPC or the inflation 245 factor, led to different optimal combinations (Table S4) . However, these frequently included one or 246 more of the classic four symptoms. Sensitivity was generally higher for combinations including 247 fatigue/weakness and/or headache, but at a cost of higher TPC, particularly for headache. Including 248 gastrointestinal symptoms had the lowest TPC and numbers to be tested, but lowest sensitivity. In 249 those 14 days post second dose, sore throat had similar effects on sensitivity and TPC as headache, 250 and in children diarrhoea had a greater benefit for sensitivity (Table S4) . 251 252 Balancing different performance metrics, adding fatigue/weakness to the classic four symptoms 253 improved sensitivity from 74% to 81%, while dropping the AUROC by <0.01 (0.734 to 0.727) (Fig.7) . 254

However, TPC increased from 4.6 to 5.3, and 1.3 times more people would need testing. This 255 combination generally performed well across subgroups (Table S5) . Adding other symptoms to the 256 classic four symptoms generally led to lower AUROCs, and at best similar sensitivity ( Table S5, Fig.7) , 257 excepting children/adolescents in whom adding headache achieved highest sensitivities when 258 considering adding only one extra symptom, and also highest AUROC for those aged under 10y 259 . CC-BY 4.0 International license It is made available under a perpetuity.

is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted August 24, 2021. ; https://doi.org/10.1101 https://doi.org/10. /2021 (Table S6) , the 263 most common symptoms presenting after the index positive were fatigue/weakness (8%), headache 264 (7%), cough (6%), loss of taste (6%), loss of smell (5%) or muscle ache/myalgia (5%) ( In a large, randomly selected community-based survey, we demonstrate that overall reporting of any 273 symptoms in new SARS-CoV-2 positives varied substantially over calendar time (40-70%), reflecting 274 changing dominance of specific variants (Alpha, Delta) and positivity rates (higher viral burden (low 275 Ct)/symptomatic infections being identified more frequently at (mostly) monthly visits when rates 276 are increasing[5]), but also background incidental changes (e.g. public awareness of SARS-CoV-2-277 associated symptoms, seasonal pathogens, schools re-opening). Additional important differences in 278 the relative frequency of symptom reporting in positive episodes vs negative visits were also 279 observed by age, sex, ethnicity and vaccination status. Broadly however, of the 12 symptoms 280 evaluated, the four classic symptoms (fever, cough, loss/change of smell/taste) gave close to optimal 281 symptom-based screening, for testing given limited capacity; where additional testing capacity is 282 available adding fatigue/weakness had the greatest improvement in sensitivity (7%) whilst inflating 283 . CC-BY 4.0 International license It is made available under a perpetuity.

is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted August 24, 2021. ; https://doi.org/10.1101 https://doi.org/10. /2021 TPC by only 15%. 284 285 Whilst the CDC approach of using a broad range of symptoms to prompt testing maximises 286 sensitivity, this approach is associated with substantially higher TPC (8.7 vs 4.6 for classic symptoms) 287 and total tests needed (2.3-fold) with associated costs and capacity requirements. The UK approach 288 of focussing on four classic symptoms has lower sensitivity (74% vs 90%), but higher accuracy to 289 detect SARS-CoV-2 symptomatic infection overall (AUROC 0.734 vs 0.593). Increases in sensitivity 290 from adding symptoms to the four classic symptoms typically either reduced overall accuracy and/or 291 increased TPC and tests needed, highlighting the importance of evaluating several test metrics. 292

Although advantages from including any additional symptoms were limited, those that best 293 improved sensitivity across multiple subgroups included either fatigue/weakness or muscle 294 ache/myalgia, or, in children/adolescents, headache. The REACT study [7] evaluating symptom 295 constellations during the Alpha wave (December-2020/January-2021) suggested adding headache, 296 muscle aches, chills and appetite loss to the classic symptoms. Our survey did not specifically elicit 297 chills or appetite loss, which may partially overlap with fever and nausea/vomiting/abdominal pain; 298 however, we found headache to have poorer specificity (i.e. to be commonly reported in test-299 negatives), particularly in adults, leading to substantially increased TPC despite improving sensitivity. 300 REACT also suggested having different symptom sets for adults and children in order to optimise 301 sensitivity, which would require careful public health messaging. ZOE[8] suggested an algorithm also 302 including working in healthcare; whilst this could theoretically be programmed into an online test 303 system, such complexity risks gaming the system if individuals cannot otherwise get a test. 304

The main limitation is that the survey collected information on only 12 specific COVID-19 symptoms, 306 plus one generic question, to minimise participant burden. We therefore could not evaluate some 307 symptoms more recently proposed for inclusion in expanded case definitions, such as coryza [13, 14] . 308 . CC-BY 4.0 International license It is made available under a perpetuity.

is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted August 24, 2021. ; https://doi.org/10.1101 https://doi.org/10. /2021 Parents/carers reported symptoms for children; symptom reporting may be affected by other 309 cultural differences we could not adjust for as well as public awareness (e.g. increased reporting of 310 loss of taste/smell once this became a "recognised" symptom). Power was limited within some 311 subgroups, e.g. children and specific non-white ethnic groups. Our survey does not include those in 312 care homes and with severe disease admitted to hospital who may have different symptom profiles. 313

Testing was predominantly monthly; although individuals were followed longitudinally, we had 314 limited resolution to assess the short-term evolution of symptoms during an infection. 315

The main study strengths are its size and population representativeness, particularly capturing 317 episodes of mild infection in the community. We took a stringent approach to defining our 'test-318 negative' comparator to limit possible contamination from undetected positives/ongoing COVID-19. 319

We report over periods that include different dominant viral variants. We took a pragmatic approach 320 to comparing test performance, taking into account trade-offs between overall accuracy, sensitivity 321 and TPC over different background prevalences, reflecting practical concerns regarding testing 322 capacity, rather than optimising individual criteria. 323 324 Overall, we did not find any major shift away from the importance of the classic four symptoms in 325 positive episodes with the emergence of the Delta variant and vaccine roll-out in the UK. Given their 326 concurrent changes in test-negatives, recent reports of associations with sore throat may reflect 327 background increases in other respiratory infections/hayfever, potentially even with SARS-CoV-2 328 isolated incidentally given that one-third of cases are estimated to be asymptomatic [2] . Currently, we 329 therefore have limited evidence for expanding the case definition beyond the classic four symptoms 330 where universal testing is not practical/affordable, with fatigue/weakness the most promising 331 candidate. However, this requires ongoing monitoring as other respiratory viruses increasingly 332 circulate following lifting of restrictions with vaccine roll-out [15] [16] [17] [18] , potentially altering the 333 . CC-BY 4.0 International license It is made available under a perpetuity.

is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted August 24, 2021. ; https://doi.org/10.1101/2021.08.19.21262231 doi: medRxiv preprint episodes vs negative visits. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted August 24, 2021. ; https://doi.org/10.1101/2021.08.19.21262231 doi: medRxiv preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted August 24, 2021. ; https://doi.org/10.1101/2021.08.19.21262231 doi: medRxiv preprint

May 2021 indicate the emergence of Alpha and Delta respectively, see Fig.S1 .

Note: models adjusted for calendar date (Fig.2) , age (Fig.3) , sex and ethnicity. Where 95% CI cross 1, there is no evidence that sex/ethnicity affects the odds of reporting that symptom given evidence of symptoms in positive episodes/negative visits. Where there is evidence of heterogeneity, there is a different effect of sex/ethnicity on reporting the symptom in positive episodes vs negative visits.

. CC-BY 4.0 International license It is made available under a perpetuity.

is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted August 24, 2021. ; https://doi.org/10.1101/2021.08.19.21262231 doi: medRxiv preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted August 24, 2021. ; https://doi.org/10.1101/2021.08.19.21262231 doi: medRxiv preprint The presence of three SARS-CoV-2 genes (ORF1ab, N, S) was identified using real-time polymerase chain reaction (RT-PCR) with the TaqPath RT-PCR COVID-19 kit (Thermo Fisher Scientific, Waltham, MA, USA), analysed using UgenTec Fast Finder 3.300.5 (TaqMan 2019-nCoV assay kit V2 UK NHS ABI 7500 v2.1; UgenTec, Hasselt, Belgium).

Choice of negative visits in the comparator group As a comparator group, we initially included all visits where PCR tests were negative, and then excluded visits where symptoms could plausibly be related to ongoing effects of COVID-19 or long COVID, where there was a high pre-test probability that the participant actually had a new COVID-19 infection that had not been detected in the survey, or where symptoms were likely driven by recent vaccination. Specifically, we excluded all negative visits (numbers in Table S1 ):

1. From -90 days before the first S-antibody positive blood test in the study prior to vaccination, where such antibody results are likely to represent previous undetected infection (these results were available only in a random subset of the population); 2. From -35 days before the first swab positive onwards from individuals who ever tested PCR positive in the study or positive on either PCR or LFD in the linked English testing programme (to avoid ongoing long COVID symptoms, 2 and COVIDrelated symptoms occurring shortly before the positive test); 3. From -35 days before any self-reported positive swab test result onwards (for the same reason; reflecting the fact that individuals may have obtained tests elsewhere) 4. From a small number of individuals who reported either loss of taste or loss of smell at their first study visit and had no national testing programme result within [-21,+21] days (all before 1 July 2020), given the high specificity of this symptom for COVID-19 infection, the fact that it would have been impossible for these individuals to get an external test at the time and the potential for subsequent symptoms to represent long COVID; 5. Where participants reported self-isolating OR contact with definite positives in the preceding 28 days (since these individuals have much higher risk of SARS-CoV-2 infection which may not have been detected) and the previous and the next visit (because of higher risk of unidentified positivity, and because they may have been contact traced through the national training programme they may be more likely to report symptoms through recall bias, regardless of status); 6. Occurring within [-7,+14 days] of either first or second vaccination date 3 , to avoid the inclusion of common symptoms caused by vaccination in the test-negative comparator group and to reflect the possibility of small inaccuracies in reported date of vaccination for some participants. Time windows were arbitrary but aligned with other analyses or windows for considering symptoms associated with positive episodes.

In order to assess the impact of various changes over the course of the epidemic, we considered symptoms overall in all positive episodes, and in specific subgroups, as follows:

a. S-gene present before 17/Nov/2020 (wild-type) vs S-gene absent from 17/Nov/2020 to 17/May/2020 (Alpha-compatible) vs S-gene present from . CC-BY 4.0 International license It is made available under a perpetuity.

is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted August 24, 2021. ; https://doi.org/10.1101/2021.08.19.21262231 doi: medRxiv preprint 17/May/2020 onwards (Delta-compatible) (Fig.S1 ); all restricted to Ct<30 to increase the chance that the survey positive test was closer to the start of the infection b. Ct<30 or 30 as a proxy for higher viral load (where symptoms may be more completely ascertained if the infection is identified close to onset) vs lower viral load c. Up to 0 days before 1 st vaccination date or unvaccinated, from 21 days post 1 st vaccination date to 13 days post 2 nd vaccination date inclusive, from 14 days post 2nd vaccination date onwards. Episodes/tests 0-20 days after first vaccination were excluded as symptoms may be due to side-effects. d. Age groups 2-5, 6-10, 11-15, 16-44, 45- Generalised additive models In regression models for reporting any evidence of symptoms and specific symptoms in those with evidence of symptoms in positive episodes and negative visits, we truncated age at 85y and Ct at the 5 th and 95 th percentiles in order to avoid undue influence of outliers. Age was modelled as smoothing spline. Due to small numbers (Table S3 ) we were only able to investigate differences by self-reported ethnicity as white vs non-white. bam(cbind(n_withsymptom, n_withoutsymptom) ~ s(study_day, bs="bs", k=15, by=Sars_COV_2_positivity) + s(age_at_visit, bs="bs", k=15, by=Sars_COV_2_positivity) + sex:Sars_COV_2_positivity + ethnicity_wo:Sars_COV_2_positivity + sex + ethnicity_wo + Sars_COV_2_positivity, family=binomial(link="cloglog"), method = "fREML", data = data, discrete=TRUE, nthreads =12) bam(cbind(n_withsymptom, n_withoutsymptom) ~ vaccinated:Sars_COV_2_positivity + vaccinated + s(study_day, bs="bs", k=15, by=Sars_COV_2_positivity) + s(age_at_visit, bs="bs", k=15, by=Sars_COV_2_positivity) + sex:Sars_COV_2_positivity + ethnicity_wo:Sars_COV_2_positivity + sex + ethnicity_wo + Sars_COV_2_positivity, family=binomial(link="cloglog"), method = "fREML", data = data, discrete=TRUE, nthreads =12)

In positive episodes only: bam(cbind(n_withsymptom, n_withoutsymptom) ~ s(ct _mean, bs="bs", k=5) + . CC-BY 4.0 International license It is made available under a perpetuity.

is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted August 24, 2021. ; https://doi.org/10.1101/2021.08.19.21262231 doi: medRxiv preprint s(study_day, bs="bs", k=15) + s(age_at_visit, bs="bs", k=15) + sex + ethnicity_wo, family=binomial(link="cloglog"), method = "fREML", data = data, discrete=TRUE, nthreads =12) Also adjusting for S-gene positivity (present/absent/unknown): bam(cbind(n_withsymptom, n_withoutsymptom) ~ s(ct _mean, bs="bs", k=5) + S_gene_positivity_pattern + s(study_day, bs="bs", k=15) + s(age_at_visit, bs="bs", k=15) + sex + ethnicity_wo, family=binomial(link="cloglog"), method = "fREML", data = data, discrete=TRUE, nthreads =12) Performance metrics For each combination of symptoms considered, we calculated the number of true positives (1 symptom from the combination being considered reported for a positive episode; TP), false positives (1 symptom reported for a negative visit; FP), true negatives (symptoms in the combination not reported for a negative visit; TN), false negatives (symptoms in the combination not reported in a positive episode; FN). We compared sensitivity=TP/(TP+FN); specificity=TN/(TN+FP); positive predictive value=TP/(TP+FP) (PPV); negative predictive value=TN/(TN+FN) (NPV); area under the receiver operating characteristic curve (AUROC), the area under the curve of specificity and 1-sensitivity, which, in this case where we have a binary outcome and a binary exposure, is 0.5*(sensitivity+specificity); tests per case identified=1/PPV (TPC); and the inflation factor=episodes/visits with 1 symptom/episodes/visits with classic symptoms.

. CC-BY 4.0 International license It is made available under a perpetuity.

is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted August 24, 2021. ; https://doi.org/10.1101/2021.08.19.21262231 doi: medRxiv preprint

Defining the negative visit comparator group Table S1 shows the total number of test-negative visits and the number of participants in which they occur, in all PCR negative visits and restricting to those visits with evidence of symptoms only, for each step of the hierarchical restriction of test-negative visits to form the comparator. This was done in order to exclude potential contamination from undetected positives, ongoing symptoms after detected positives, and symptoms due to vaccination. Overall, 75% of test-negative visits in 93% participants with any test-negative visit were retained in analyses, and 62% of test-negative visits where any symptoms were reported in 68% of participants with any test-negative visit where any symptoms were reported. Most test-negative visits were excluded because of self-isolation or contact with definite positives. The larger exclusion of test-negative visits where any symptoms were reported, despite the fact that symptoms were not a reason for exclusion (with the exception of visits from a small number of individuals reporting loss of taste/smell in 2020 before tests were available) illustrate the likely contamination of all test-negative visits with both undetected positives and ongoing symptoms post COVID-19 infection ( Table S2) .

Comparing the probability of reporting specific symptoms in negative visits with evidence of symptoms over time before (Fig.S10 ) and after (Fig.2 ) the final exclusion of negative visits that occurred within [-7,+14 days] of either first or second vaccination date, the substantially higher probabilities of reporting fever, headache, fatigue weakness, muscle ache myalgia and nausea-vomiting in the first quarter of 2021 are plausibly driven by side effects of vaccination, as these probabilities markedly reduce after the exclusion. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted August 24, 2021. ; https://doi.org/10.1101/2021.08.19.21262231 doi: medRxiv preprint 37 Figure S3 . Probability of reporting any evidence of symptoms, as well as the probability of reporting each of the 12 symptoms in those with evidence of symptoms by mean Ct (model adjusted for age, sex and ethnicity and S-gene positivity pattern). Figure S4 . Performance of individual symptoms, as well as the classic four symptoms (cough, fever, loss of taste/smell), classic plus all possible combinations of 1/2/3/4 symptoms, and any of the 12 named symptoms, in predicting SARS-CoV-2 positivity in those with evidence of symptoms in terms of sensitivity and overall accuracy (AUROC).

B. Ct 30 Figure S5 . Performance of individual symptoms, as well as the classic four symptoms (cough, fever, loss of taste/smell), classic plus all possible combinations of 1

A. Wild type, Ct<30 B. Alpha-compatible, Ct<30 C. Delta-compatible, Ct<30 Figure S6 . Performance of individual symptoms, as well as the classic four symptoms (cough, fever, loss of taste/smell), classic plus all possible combinations of 1

A. not yet vaccinated B. 21 days post 1 st vaccination C. 14 days post 2 nd vaccination and before 2 nd vaccination Figure S7 . Performance of individual symptoms, as well as the classic four symptoms (cough, fever, loss of taste/smell), classic plus all possible combinations of 1/2/3/4 symptoms, and any of the 12 named symptoms, in predicting SARS-CoV-2 positivity in those with evidence of symptoms in terms of sensitivity and overall accuracy (AUROC). 

A. 26/Apr/2020-1/Sep/2020 B. 1/Sep/2020-17/Nov/2020 C.17/Nov/2020-1/Mar/2021 Figure S9 . Distribution of Ct for each of the 12 symptoms in positive episodes with symptoms absent at all visits within 35 days of the index positive (00), absent at the index positive, but present at least one subsequent visit (01), present at the index positive, but absent at subsequent visits (10), present initially and at least one subsequent visit (11) . CC-BY 4.0 International license It is made available under a perpetuity.

is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted August 24, 2021. ; https://doi.org/10.1101/2021.08.19.21262231 doi: medRxiv preprint Figure S10 .

Note: adjusted for sex, age and ethnicity (reference category age 45, male, white ethnicity). Vaccination programme started 8 December 2020, but increased in magnitude in January 2021. From -35 days before the first positive onwards from individuals who ever tested PCR positive in the study or in the linked English testing programme (to avoid ongoing long COVID symptoms, 2 and COVID-19-related symptoms shortly before the positive test); 3. From -35 days before any self-reported positive swab test result onwards (for the same reason; reflecting the fact that individuals may have obtained tests elsewhere) 4. From a small number of individuals who reported either loss of taste or loss of smell at their first study visit and had no national testing programme result within [-21,+21] days (all before 1 July 2020), given the high specificity of this symptom for COVID-19 infection, the fact that it would have been impossible for these individuals to get an external test and the potential for subsequent symptoms to represent long COVID 5. Where participants reported self-isolating OR contact with definite positives in the preceding 28 days (since these individuals have much higher risk of SARS-CoV-2 infection which may not have been detected) and the previous and the next visit (because of higher risk of unidentified positivity, and because they may have been contact traced through the national training programme they may be more likely to report symptoms through recall bias, regardless of status) 6. Occurring within [-7,+14 days] of either first or second vaccination date 3 , to avoid the inclusion of common symptoms caused by vaccination in the test-negative comparator group and to reflect the possibility of small inaccuracies in reported date of vaccination for some participants . CC-BY 4.0 International license It is made available under a perpetuity.

is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted August 24, 2021. ; https://doi.org/10.1101 https://doi.org/10. /2021 is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted August 24, 2021. ; https://doi.org/10.1101 https://doi.org/10. /2021 is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted August 24, 2021. ; https://doi.org/10.1101 https://doi.org/10. /2021 is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted August 24, 2021. ; https://doi.org/10.1101 https://doi.org/10. /2021 (5) classic or muscle ache/myalgia (5) classic or headache (5) classic or diarrhoea (5) 

AUROC >90 th quantile, sensitivity > sensitivity of combination of classic 4 symptoms). Inflation (relative numbers reporting these symptoms compared to classic symptoms) and tests per positive case (TPC) are also included in the visualisation

Abdominal pain -AP, Diarrhoea -D, Sore throat -ST, Cough -C, Shortness of breath -SOB, Loss of taste -LT, Loss of smell -LS, Loss of taste or smell -LTS Note: Bottom row is an expanded version of the top right corner of the top row panels (red box, AUROC >90 th quantile, sensitivity > sensitivity of combination of classic 4 symptoms). Inflation (relative numbers reporting these symptoms compared to classic symptoms) and tests per positive case (TPC) are also included in the visualisation

Muscle ache/myalgia -MAM, Weakness/tiredness -FW, Nausea/vomiting -NV, Abdominal pain -AP, Diarrhoea -D, Sore throat -ST, Cough -C, Shortness of breath -SOB, Loss of taste -LT, Loss of smell -LS

066 (41%) 2,750 (37%) 2,418 (32%) loss of taste 7,572 6,941 (92%) 6,036 (80%) 5,242 (69%) 4,806 (63%) 4,193 (55%) 3,125 (41%) 2,779 (37%) 2,415 (32%) loss of taste or smell 10

Note: For any number of symptoms, the combinations achieving the highest sensitivity and highest AUROC are shown in bold, and optimizing both in grey 4 shading and bold, excluding the combination of any of the 12 named symptoms, given they achieve the highest sensitivity by definition shortness of breath (5) classic or sore throat (5) classic or abdominal pain (5) classic or nausea/vomiting

Symptoms sensitivity specificity AUROC TPC inflation Note: symptoms are ordered from highest to lowest percentage of positive episodes where the symptom was absent at index positive, but present at at least one subsequent visit in the next 35 days 14 15